trending Market Intelligence /marketintelligence/en/news-insights/trending/YfNyG9HkJggQo_xVs5gczA2 content esgSubNav
In This List

Albany Molecular Research to be acquired by GTCR, Carlyle Group


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Albany Molecular Research to be acquired by GTCR, Carlyle Group

Private equity firms GTCR LLC and The Carlyle Group LLC are acquiring N.Y.-based Albany Molecular Research Inc. for $21.75 per share in cash.

The cash consideration represents a 42% premium to the 60-day weighted average closing stock price as of April 5, the last trading day prior to public rumors regarding a potential sale process.

The Albany Molecular board has unanimously approved the deal and has recommended shareholders to vote in favor of it. The acquisition is subject to customary closing conditions and is expected to close during the third quarter.

The transaction will be financed through a combination of debt and equity financing.

Credit Suisse Securities (USA) LLC and Goodwin Procter LLP are advising Albany Molecular on the deal.

Latham & Watkins LLP, Barclays and Morgan Stanley & Co. LLC are advising Carlyle. GTCR is being advised by Kirkland & Ellis LLP and RBC Capital Markets LLC.